Wayne P. Rothbaum
Director/Board Member at IOVANCE BIOTHERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Iain Dukes | M | 65 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | 8 years |
| Maria Fardis | M | 56 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | 6 years |
| Frederick Vogt | M | 50 | 8 years | |
| Merrill McPeak | M | 88 | 13 years | |
| Jean-Marc Bellemin | M | 51 | 4 years | |
| Victor Seitles | M | - |
Quogue Capital LLC
 Quogue Capital LLC Investment ManagersFinance Quogue Capital LLC (Quogue Capital) is a private equity firm founded in 2002 by Wayne P. Rothbaum. The firm is headquartered in New York.
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | 9 years |
| Sara Pellegrino | F | - | - | |
| Flavia Borellini | M | 64 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | 8 years |
| Michael Weiser | M | 61 | 6 years | |
| Jesse Seton McGreivy | M | 54 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | - |
| Athena Countouriotis | M | 52 | 5 years | |
| Ryan Maynard | M | 54 | 9 years | |
| Wendy Yarno | F | 69 | 1 years | |
| Jim Ziegler | M | - | 4 years | |
| Igor Bilinsky | M | 51 | 3 years | |
| Roger Ulrich | M | - |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | - |
| Friedrich Finckenstein | M | 51 | 5 years | |
| Raj K. Puri | M | - | 2 years | |
| Brian Shew | M | - | 3 years | |
| Tracy Winton | F | - | 4 years | |
| Jen Saunders | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Timothy Morris | M | 61 | 3 years | |
| Michael Swartzburg | M | 57 | 3 years | |
| Peter van Amson | M | - |
State University of New York at Binghamton
| 6 years |
| Kwasi Speede | M | - |
State University of New York at Binghamton
| 7 years |
| Jay Venkatesan | M | 52 | 5 years | |
| Molly Henderson | F | 54 | 1 years | |
| Michael Bebel | M | - |
State University of New York at Binghamton
| 6 years |
| Raquel Izumi | M | 54 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | 7 years |
| Franco Valle | M | 43 | 2 years | |
| Sanford J. Hillsberg | M | 75 | 5 years | |
| Wendy Dixon | M | 68 | 1 years | |
| Debora Barton | M | 48 | 1 years | |
| Raymond Stapleton | M | - | - | |
| Rachel Nachas Schatten | F | 53 |
State University of New York at Binghamton
| 4 years |
| Dan Rootenberg | M | - |
State University of New York at Binghamton
| 4 years |
| Steven D. Lash | M | - |
State University of New York at Binghamton
| 4 years |
| Jim Casey | M | - |
State University of New York at Binghamton
| 4 years |
| David Keith Skolnik | M | - |
State University of New York at Binghamton
| 3 years |
| Deanna Franceschini | F | - |
State University of New York at Binghamton
| 4 years |
| Phillip A. Bottari | M | - |
State University of New York at Binghamton
| 4 years |
| Howard Steinberg | M | - |
State University of New York at Binghamton
| 4 years |
| Matt Furman | M | 54 |
State University of New York at Binghamton
| 4 years |
| Adam Gazzaley | M | 55 |
State University of New York at Binghamton
| 4 years |
| Stephen Manaker | M | - |
State University of New York at Binghamton
| 4 years |
| Kristin Lanzi | F | - | - | |
| Ted Kim | M | - |
State University of New York at Binghamton
| 4 years |
| David Johnson | M | 59 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | 3 years |
| Michael T. Lotze | M | - | 1 years | |
| Moira O'Reilly | F | - |
State University of New York at Binghamton
| 5 years |
| David Vogt | M | - |
State University of New York at Binghamton
| 4 years |
| Jane Huang | M | 51 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | 1 years |
| Richard Gaeto | M | - | - | |
| Xiang Fei | M | 52 |
State University of New York at Binghamton
| 4 years |
| Igor Gorbatchevsky | M | - | 1 years | |
| Diane Morgan | F | - |
State University of New York at Binghamton
| 4 years |
| David Vogt | M | - |
State University of New York at Binghamton
| 4 years |
| Liu Bobby | M | - |
State University of New York at Binghamton
| 4 years |
| Christopher Carl Andersen | M | - |
State University of New York at Binghamton
| 4 years |
| Joel Gallo | M | 51 |
State University of New York at Binghamton
| 4 years |
| Corinne Epperly | M | 46 | 1 years | |
| Andrew K. Chaglasian | M | - |
State University of New York at Binghamton
| 4 years |
| Eric M. Krautheimer | M | - |
State University of New York at Binghamton
| 4 years |
| Gregory Schiffman | M | 67 | 1 years | |
| Ephraim Bernstein | M | - |
State University of New York at Binghamton
| 4 years |
| Eleanor Innes | F | - |
State University of New York at Binghamton
| 3 years |
| David Laurence Dineen | M | - |
State University of New York at Binghamton
| 4 years |
| Alex Piccolo | M | - |
State University of New York at Binghamton
| 1 years |
| Michael Abata | M | - |
State University of New York at Binghamton
| 4 years |
| Paul L. Robinson | M | 57 |
State University of New York at Binghamton
| 4 years |
| Rob Goldstein | M | 50 |
State University of New York at Binghamton
| 4 years |
| Eric D. Storch | M | - |
State University of New York at Binghamton
| 4 years |
| David Clark | M | - |
State University of New York at Binghamton
| 4 years |
| Stephen Michael Beinhacker | M | - |
State University of New York at Binghamton
| 4 years |
| Gregg Hymowitz | M | 59 |
State University of New York at Binghamton
| 4 years |
| Gary Bachman | M | 56 |
State University of New York at Binghamton
| 4 years |
| Jeffrey Holman | M | 56 |
State University of New York at Binghamton
| 4 years |
| Daniel Sessa | M | 59 |
State University of New York at Binghamton
| 4 years |
| Kenneth A. Goldblatt | M | - |
State University of New York at Binghamton
| 4 years |
| Jordan D. Alexander | M | - |
State University of New York at Binghamton
| 4 years |
| Michael Intrator | M | - |
State University of New York at Binghamton
| 4 years |
| Marc Estigarribia | M | 63 |
State University of New York at Binghamton
| 4 years |
| Todd Green | M | - |
State University of New York at Binghamton
| 4 years |
| Lawrence Heilbronner-Kolthoff | M | 58 |
State University of New York at Binghamton
| 4 years |
| Shu Yao Wang | M | - |
State University of New York at Binghamton
| 5 years |
| Janice W. Chan | F | - |
State University of New York at Binghamton
| 4 years |
| Belinda Field | M | - |
State University of New York at Binghamton
| 4 years |
| Steven Bisgay | M | 57 |
State University of New York at Binghamton
| 4 years |
| Jeff E. Silverman | M | 60 |
State University of New York at Binghamton
| 3 years |
| Randall L. Borkenstein | M | - |
State University of New York at Binghamton
| 4 years |
| Steven A. Fischkoff | M | - | - | |
| Christopher J. Fearnley | M | - |
State University of New York at Binghamton
| 4 years |
| Andrew Hamer | M | 60 |
State University of New York at Binghamton
| 4 years |
| Scott Wharton | M | - |
State University of New York at Binghamton
| 4 years |
| David Polson | M | - |
State University of New York at Binghamton
| 4 years |
| Ed Groshans | M | - |
State University of New York at Binghamton
| 5 years |
| Michelle Teitsch | F | - |
State University of New York at Binghamton
| 4 years |
| jennifer lee | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 96.94% |
| Netherlands | 5 | 5.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Wayne P. Rothbaum
- Personal Network